RecruitingNCT06069505

Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Patients With an Invasive Aspergillus Infection Azole Resistance PCR Optimalization-study


Sponsor

Bart Rijnders

Enrollment

300 participants

Start Date

Jul 1, 2017

Study Type

OBSERVATIONAL

Conditions

Summary

Invasive aspergillosis (IA) is the most common mould infection in immunocompromised patients with haematological disease. Voriconazole, a triazole, improves overall survival of patients with an IA and is the mainstay of therapy. Resistance of A. Fumigatus emerged as an important clinical problem and infections with azole resistant Aspergillus have a high mortality. Nowhere in the world, azole resistance is more prevalent than in the Netherlands. Rapid detection of resistance is key to improve the patient's outcome but fungal cultures take time and are often negative. The investigators aim to detect azole resistance associated mutations in fungal DNA extracted directly from serum or plasma to accelerate diagnosis and improve outcome of patients infected with azole resistant A. fumigatus.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • years or older.
  • Lung CT shows lesions that fulfil the EORTC/MSG radiological criteria of possible invasive fungal infection.
  • A bronchoalveolar lavage is planned or has been performed \<48hrs earlier

Exclusion Criteria1

  • \- Patients unable or unwilling to provide consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTAspergillus PCR

Aspergillus PCR will be performed on different volumes of serum and plasma of patients with hematological malignancies with suspicion for invasive fungal infection.


Locations(1)

Erasmus Medical Center (EMC)

Rotterdam, South Holland, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06069505


Related Trials